SyntheX
PrivateLast Round
Series A
Jan 11, 2024
Est. Valuation
$3.13M
Total Funding Raised
$18.05M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
SyntheX operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series A round in January 2024.
SyntheX is a biotechnology company that utilizes genetically engineered circuits and proprietary DNA-encoded libraries to discover novel therapeutics for cancer and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SyntheX Comparables
Compare SyntheX with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Proxygen | 87% | |
| Degron Therapeutics | 83% | |
| Bullseye Biosciences | 82% |
For institutional investors. Book with your work email.
SyntheX Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 11, 2024 | ||||
| Debt | Apr 27, 2020 | ||||
| Seed | Apr 27, 2017 | ||||
| Seed | Feb 14, 2017 | ||||
| Accelerator | Jul 15, 2016 | ||||
Accelerator | Mar 1, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SyntheX Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Morgan Noble Healthcare Partners | Series A |
| IndieBio | Seed, Accelerator |
| Oriza Ventures | Seed, Series A |
| OMX Ventures | Seed, Series A |
| 8VC | Seed, Series A |
| SOSV | Accelerator, Seed, Series A |
| SVB Financial Group | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2026
Grew 17% QoQ, from 36 to 42 employees.
- Jun 28, 2026
Grew 18% QoQ, from 34 to 40 employees.
For institutional investors. Book with your work email.
SyntheX Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SyntheX's valuation, stock price, and market status.
Is SyntheX a public or private company?
SyntheX is a private company.
What is the current stock price of SyntheX?
SyntheX is a private company, so its shares have no public market price. Caplight tracks SyntheX's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SyntheX worth (valuation)?
SyntheX's valuation is estimated at $3.1M based on funding round data.
Can I buy SyntheX stock?
SyntheX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SyntheX's last funding round?
SyntheX's most recent funding round was Series A on January 11, 2024.
Who are the main investors in SyntheX?
Key investors in SyntheX include IndieBio.
Will SyntheX IPO soon?
No public IPO plans have been announced for SyntheX.
How can I track SyntheX secondary market activity?
Caplight tracks bids, offers, and trades in SyntheX's shares on secondary markets.